AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess:
- Part A: the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of
AsiDNA in patients with advanced solid tumors.
- Part B: the safety and preliminary efficacy of AsiDNA in combination with Carboplatin
with or without Paclitaxel in patients with Advanced solid tumors.